Cryo Cell International (CCEL) Common Equity (2010 - 2026)

Cryo Cell International has disclosed Common Equity across 17 years of filings, most recently posting -$18.4 million for Q1 2026.

• In Q1 2026, Common Equity fell 25.55% year-over-year to -$18.4 million; the TTM figure through Feb 2026 stood at -$18.4 million (down 25.55% YoY), while the FY2025 annual figure was -$18.6 million, down 40.78% from the prior year.
• Common Equity advanced to -$18.4 million in Q1 2026, from -$18.6 million in the prior quarter.
• Over the last five years, Common Equity for CCEL reached as high as $4.4 million in Q2 2022 and fell as low as -$18.6 million in Q4 2025.
• The 5-year median for Common Equity is -$10.3 million (2024), against an average of -$7.9 million.
• Annual changes were most pronounced in 2022 — Common Equity soared 350.8% — and 2024, when it tumbled 59040.98%.
• A 5-year view of Common Equity shows it stood at -$1.5 million in 2022, then slumped by 623.69% to -$11.0 million in 2023, then retreated by 19.81% to -$13.2 million in 2024, then plunged by 40.78% to -$18.6 million in 2025, then advanced by 1.11% to -$18.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$18.4 million, -$18.6 million, and -$14.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.